Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)

China flag China · Delayed Price · Currency is CNY
23.49
+0.28 (1.21%)
At close: Jun 12, 2026
Market Cap1.30B +0.5%
Revenue (ttm)162.81M -28.7%
Net Income-58.72M
EPS-1.06
Shares Out 55.19M
PE Ration/a
Forward PEn/a
Dividend0.34 (1.45%)
Ex-Dividend Daten/a
Volume1,179,242
Open23.21
Previous Close23.21
Day's Range22.76 - 23.90
52-Week Range22.68 - 36.00
Beta0.33
AnalystsStrong Buy
Price Targetn/a
Earnings DateAug 28, 2026

About SHA:688217

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to leukemia, lymphoma, solid tumors, and infectious diseases. In addi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 336
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688217
Full Company Profile

Financial Performance

In 2025, SHA:688217's revenue was 177.26 million, a decrease of -26.84% compared to the previous year's 242.31 million. Losses were -50.38 million, 219.6% more than in 2024.

Financial Statements